Hormonal contraceptives further increase risk for depression in young women with ADHD

A studyopens in new tab/window in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), published by Elsevier, reports that girls and young women with attention deficit hyperactivity disorder (ADHD) have a high risk of depression, which is increased with the use of oral contraceptive pills. Women aged 15-24 with ADHD had a three-fold higher risk of developing depression overall and were at least five times more at risk than their peers not affected by ADHD irrespective of oral contraceptives.

Overall, 41.9% of women with ADHD developed depression or were prescribed antidepressants during the study period, whereas, the corresponding number in women without ADHD was 10.5%. Girls and young women with ADHD had three times increased risk of developing depression compared to those without ADHD. Other independent risk factors for depression were age, education levels, parental history of mental health diagnoses or suicide, and each of the medical indications for hormonal contraceptive use-acne, dysfunctional bleeding, dysmenorrhea, endometriosis, and PCOS.

In this large nationwide Swedish register study, the researchers set out to explore potential adverse effects of hormonal contraception, including depression, that may affect adherence to user-dependent contraception and increase the risk for unplanned pregnancies and teenage birth in women with ADHD.  In this sample, 29,767 girls and young women with ADHD aged 15 to 24 years and 763,146 without ADHD provided were included through diagnostic codes for ADHD and prescription of stimulant medication, contraceptives, and antidepressant medication.

Young women have the highest risk to develop psychiatric conditions in comparison with women and men of all age groups. Unintended early pregnancies overlap with formative academic and occupational years, interfering with the economic and psychosocial life trajectory of individuals experiencing this risk factor.

It is not known if these young women are more susceptible to adverse effects of hormonal contraceptives, compared to women without ADHD. This study is important as the most tolerable contraceptive methods should be used to prevent the risk of unplanned and unwanted pregnancies in vulnerable groups such as young women with ADHD. Teenage parents are at risk for low educational attainment, welfare dependency, and becoming single parents.

In addition, their children are at increased risk for perinatal morbidity and mortality, low socioeconomic status, and low quality of life, effectively transmitting psychosocial vulnerability across generations. Other types of non-oral contraceptives (e.g. – patches, implants, injections) were not associated with an elevated risk for depression in women with ADHD. Thus, integrating information on risks with hormonal contraceptives as well as the potential benefits of long-acting reversible contraceptives in shared decision-making and contraception counseling for young women with ADHD has the potential to affect public mental health in generations to come.

---

Notes for editors

The article is "Hormonal Contraceptive Use and Risk of Depression Among Young Women With Attention-Deficit/Hyperactivity Disorder," by Cecilia Lundin, MD, PhD, Anna Wikman, PhD, Per Wikman, PhD, Helena Kopp Kallner, MD, PhD, Inger Sundstrom-Poromaa, MD, PhD, Charlotte Skoglund, MD, PhD (https://doi.org/10.1016/j.jaac.2022.07.847). It appears in the Journal of the American Academy of Child and Adolescent Psychiatry, volume 62, issue 6 (June 2023), published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Charlotte Skoglund, MD, PhD, at [email protected].

About JAACAP

Journal of the American Academy of Child and Adolescent Psychiatryopens in new tab/window (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.

The Journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The Journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.